Diabetes Technology & TherapeuticsEarly Initiation of Automated Insulin Delivery at Type 1 Diabetes Diagnosis in Children and Adolescents Is Associated with Improved Outcomes

ℹ️ Observational Association Only Evidence
A retrospective cohort study of 9,856 youth across 27 US pediatric centers diagnosed with T1D between 2020 and 2022 evaluated whether AID initiation timing affected 24-month glycemic outcomes and DKA rates. Participants were grouped by AID initiation at <6, 6–12, 13–24 months, or no AID use.

Clinical Considerations

• AID initiation within 6 months was associated with median HbA1c of 7.1% at 24 months versus 9.8% in non-AID users (P < 0.001).
• DKA rates were threefold higher in non-AID users compared with the early-initiation group across the 24-month follow-up.
• In adjusted models, early initiation showed 1.82 times higher odds of HbA1c below 7% and 0.27 odds of HbA1c above 9% at 24 months versus non-users.
• Models adjusted for age, gender, race and ethnicity, insurance, language, diabetes duration, and baseline HbA1c, though residual confounding around access and engagement cannot be excluded.

Practice Applications

• Consider AID candidacy discussions at or near diagnosis rather than deferring until after a stabilization period.
• Recognize that 50% public-insurance representation in this cohort supports relevance across payer mix, though access barriers persist.
• Integrate equity considerations into AID referral pathways, since timing benefits accrue to those who reach the technology first.
• Monitor for DKA risk reduction as a meaningful secondary outcome of earlier AID adoption, alongside glycemic targets.